What is Selank used for here?

This product is sold only as a laboratory research chemical, not a medicine, and is not for human or veterinary use. Separately, Selank is an approved medicine in Russia for anxiety disorders and neurasthenia (a 0.15% nasal drops preparation), but it holds no EU or US marketing authorisation.

What is Selank's structure, and how is its identity confirmed?

Selank is a synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its identity is checked by mass spectrometry (an intact-mass result consistent with the expected mass supports identity but does not by itself prove exact sequence) alongside an HPLC purity result on the batch certificate of analysis.

Is Selank the same molecule as Tuftsin?

No. Tuftsin is a natural tetrapeptide (Thr-Lys-Pro-Arg) derived from immunoglobulin G. Selank is a synthetic analogue that extends the tuftsin sequence with a C-terminal Pro-Gly-Pro motif, associated with increased resistance to proteolytic degradation. They are related but distinct molecules.

Is Selank a benzodiazepine?

No. Selank is a peptide, not a benzodiazepine. Preclinical gene-expression and in vitro binding studies associate Selank with GABA-system endpoints through a proposed allosteric mechanism, while some animal studies reported no benzodiazepine-like sedation under their test conditions. Whether that separation holds in humans has not been established by controlled clinical data, so an absence of sedation or dependence in people should not be assumed.

How does Selank differ from Semax?

Both are Pro-Gly-Pro-stabilised peptides from the same Russian institute, but they are studied for different endpoints: Selank mainly for anxiety-related and GABA-system endpoints, Semax mainly for cognitive and neurotrophin-related endpoints. They are distinct molecules with distinct preclinical literatures, and neither has an established human clinical effect outside its Russian approval context.

Can Selank be combined with Semax?

No published human study has tested combined Semax and Selank administration. The main human imaging study (Panikratova et al., 2020, PMID 32342318) administered Semax, Selank or placebo SEPARATELY. PeptidesDirect does offer a pre-mixed Semax/Selank blend for protocols that want both in one vial, but a combined-administration benefit has not been demonstrated.

Are there human studies on Selank?

Human data are limited and mostly from the Russian clinical context. A small Russian study (Zozulia et al., 2008) reported an anxiolytic effect in generalized anxiety disorder, and Panikratova et al. (2020) examined resting-state connectivity after separate Semax or Selank administration. These do not establish efficacy for the research-grade material sold here, and there is no large controlled international trial.

What side effects has Selank shown in the published research?

The small Russian clinical studies described Selank as generally well tolerated, without the sedation typical of benzodiazepines, but they did not provide systematic adverse-event reporting and were not large controlled trials. No independent long-term human safety data exist for the peptide as an internationally distributed research chemical, so any tolerability characterisation should be treated as preliminary.

Are there known interactions between Selank and other centrally active compounds?

There is no controlled interaction study of research-grade Selank with other central nervous system compounds. Its reported effects on GABA-system and monoamine-related endpoints are preclinical, so potential interactions in a research setting are not characterised and should be treated as an open variable in experimental design.

Is Selank legal to buy for research in the EU?

Selank is an approved medicine in Russia but holds no EU marketing authorisation. There is no single EU-wide category for research peptides, so legality depends on presentation, intended use and each member state's national law. We sell strictly for laboratory research and not for human consumption; confirm the rules with your national competent authority and your institution, and treat this as general information, not legal advice.

Is Selank a banned substance for athletes, and would it show on a drug test?

Selank is not specifically named on the World Anti-Doping Agency Prohibited List, but the list includes broad categories and is updated regularly, so athletes subject to testing should verify the current status themselves and treat any unapproved peptide with caution. It is not part of a standard workplace drug-screen panel, but this is a research chemical not intended for any human use.

How does Selank differ from N-Acetyl Selank Amidate?

N-Acetyl Selank Amidate is a chemically modified version of Selank (with an acetyl group and a C-terminal amide) intended to alter stability or delivery. It is a different molecule from plain Selank, so a certificate of analysis should confirm which form a product actually is; findings for one form do not automatically transfer to the other.

How does Selank's proposed mechanism compare with SSRIs?

They are studied through different mechanisms. SSRIs increase synaptic serotonin by blocking its reuptake; Selank's reported preclinical effects are associated with GABA-system gene expression and monoamine-related endpoints rather than a defined reuptake mechanism, and its molecular targets are not fully established. Selank is a research compound, not an SSRI substitute, and no clinical head-to-head comparison exists.

Who tests Selank batches, and is it independent?

The current Selank batch carries a manufacturer-supplied Janoshik certificate of analysis; PeptidesDirect did not commission or independently retest it, and Selank is not among the products for which the shop commissioned its own independent laboratory report. Match the lot number on the vial to the certificate and see the current record at /coa.

What doses of Selank have research studies used?

No controlled human dosing protocol has been published for research-grade Selank. Russian labeling for the authorised 0.15% nasal drops medicine specifies 2 drops into each nostril 3 times daily; this applies only to that Russian medicine, and the indexed Zozulia abstract does not report the absolute dose. Animal studies reported approximately 100 to 300 µg/kg, mainly intranasally or intraperitoneally. These are study or labeling figures, not a recommendation, and they do not convert into a human protocol.

How is Selank reconstituted for laboratory use?

Add a validated solvent slowly down the vial wall and mix by gentle swirling rather than vigorous shaking. A syringe is used only as a laboratory measuring tool to add solvent and withdraw aliquots for research, not for injection into a person or animal. Follow the specific product's documentation for the solvent and concentration; there is no validated fixed post-reconstitution shelf life, so treat a reconstituted vial as a short-lived working solution.

Buy Selank: Tuftsin Analogue for Neuroscience Research

Selank is a synthetic heptapeptide developed, like Semax, at the Institute of Molecular Genetics of the Russian Academy of Sciences. As a synthetic analogue of the endogenous immune peptide Tuftsin, Selank has been studied for anxiety-related, GABA-system, monoamine and immune endpoints, mostly in Russian preclinical work. These are separate lines of research; the descriptions below are preclinical findings, not established clinical effects.

Selankcognitive

Synthetic tuftsin analog with anxiolytic, nootropic, and immunomodulatory properties. Developed at the Russian Academy of Sciences.

Selank is often contrasted with benzodiazepines because, in the animal models studied, it affected GABA-system-related endpoints without the sedation seen with benzodiazepines. Whether that separation holds in humans has not been established by controlled clinical data.

What Is Selank?

Selank is a heptapeptide with the amino acid sequence:

Thr-Lys-Pro-Arg-Pro-Gly-Pro

It is a synthetic analogue of Tuftsin (Thr-Lys-Pro-Arg), a naturally occurring tetrapeptide found in the body as part of immunoglobulin G (IgG). Tuftsin is known as an endogenous immunomodulator - it activates phagocytes and modulates the innate immune response.

Selank extends the Tuftsin sequence with the C-terminal tripeptide Pro-Gly-Pro. Preclinical literature associates this motif with greater resistance to proteolytic degradation; it does not establish Selank's biological half-life in humans.

In Russia, Selank is an approved medicine for anxiety disorders and neurasthenia as 0.15% nasal drops. Selank has no EU marketing authorisation and no US FDA approval.

Why Is Selank Being Researched?

Key Studies

Volkova et al. (2016, Frontiers in Pharmacology, PMID 26924987): This rat study reported that Selank administration affected the expression of some genes involved in GABAergic neurotransmission; the authors described allosteric modulation as a possible mechanism. It did not establish enhanced inhibitory transmission or a human effect.

Kozlovskii and Danchev (2002, Zh Vyssh Nerv Deiat Im I P Pavlova, PMID 12449836): This rat study assessed learning in an active avoidance conditioning task. It did not report elevated plus maze, open-field or conflict-test data, and it did not establish a non-sedating anxiolytic effect.

Zozulia et al. (2008, Zh Nevrol Psikhiatr Im S S Korsakova, PMID 18454096): This randomized active-comparator study included 62 patients, with 30 receiving Selank and 32 medazepam. The indexed abstract reports similar anxiolytic scale effects and additional antiasthenic and psychostimulant effects with Selank. The study had no placebo arm, and it does not establish efficacy or safety for the research-grade material sold here.

Ershov et al. (2009, Voprosy Virusologii, PMID 19882898): This preclinical study tested Selank against influenza A/Aichi/2/68 (H3N2) in vitro and in laboratory animals. It did not test HSV-1, HSV-2 or cytomegalovirus. Separately, Kolomin et al. (2014, Molecular Immunology, PMID 24291245) examined inflammation-related gene expression in mouse spleen. Neither study establishes clinical antiviral or immunomodulatory effects.

Vasil'eva et al. (2020, Neurochemical Journal): This Russian preclinical study compared Selank, Semax and Noopept given SEPARATELY by different routes. In BALB/c mice, route-dependent nootropic and anxiolytic effects were reported; C57BL/6 mice largely did not show the same effects. The strain and route dependence mean these are model-specific preclinical findings.

Mechanisms of Action

Preclinical studies associate Selank with several signalling effects, reported separately and mostly in Russian preclinical work; these do not establish clinical effects:

GABA-system findings (preclinical): In rat gene-expression studies, Selank affected genes involved in GABAergic neurotransmission, with allosteric modulation proposed as a possible mechanism. This does not establish enhanced inhibitory transmission, an absence of sedation, or dependence liability in humans.
Monoamine-related findings (preclinical): Mouse studies reported region- and strain-dependent changes in norepinephrine and dopamine metabolites after Selank administration. These findings do not establish antidepressant or mood-stabilizing effects in humans. Enkephalin-degrading enzymes degrade peptides, not serotonin or noradrenaline.
Immune-related findings (preclinical): As a tuftsin analogue, Selank has been studied for immune effects; preclinical work reported changes in cytokine-related gene expression and antiviral activity in laboratory models. These findings do not establish clinical immunomodulation.
Neurotrophin-related findings (preclinical): Some preclinical work has reported effects of Selank on BDNF expression. This is a proposed contributor to nootropic-related endpoints in animal models, not an established human effect.
Inflammation-related gene-expression findings (preclinical): Mouse-spleen studies reported changes in inflammation-related mRNA after Selank administration. They do not establish that these changes cause anxiolytic effects or clinical immunomodulation.

Quality Criteria When Purchasing

Reported HPLC purity on the batch CoA: Check the reported HPLC purity on the current batch certificate and set an acceptance threshold appropriate to your experiment rather than relying on a single fixed number.
Mass Spectrometry: An intact-mass result consistent with the expected mass supports identity but does not by itself prove exact sequence or purity; read it with the HPLC result.
Which lab, and what was tested: The current Selank batch carries a manufacturer-supplied Janoshik report; PeptidesDirect did not commission or independently retest it. The certificate is listed on our lab-reports page at /coa.
Net peptide content: A useful certificate reports net peptide content (the actual peptide after counterions, residual moisture and TFA), which differs from HPLC purity.

Dose Figures in the Research Literature

No controlled human dosing protocol has been published for research-grade Selank. The figures below are references from the literature or Russian labeling, not a dosage recommendation:

Russian labeling (intranasal): The authorised 0.15% nasal drops product specifies 2 drops into each nostril 3 times daily. This is a labeling figure for the Russian medicine, not a protocol for the research-grade material sold here; the indexed Zozulia abstract does not state its absolute Selank dose.
Animal models (intranasal or intraperitoneal): Published studies reported approximately 100 to 300 µg/kg. In the Vasil'eva et al. comparison, route affected the anxiolytic and nootropic readouts differently, and the effects were strain-dependent.

These are study or labeling figures, not recommendations. No controlled human dosing protocol exists for the research-grade material sold here.

Storage

Selank is supplied as lyophilized powder:

Before reconstitution: Follow the supplier's documented storage for the unopened lyophilized material, kept cold and protected from light and moisture.
After reconstitution: There is no single validated post-reconstitution shelf life for Selank; treat a reconstituted vial as a short-lived working solution, keep it cold, and rely on the specific product's stability data and your own contamination controls rather than a fixed number of weeks.
Reconstitution: Add a validated solvent slowly down the vial wall and mix by gentle swirling rather than vigorous shaking.
Light protection: Protect from light as a precautionary storage condition.

Why Buy Selank from PeptidesDirect?

Documented certificate: A manufacturer-supplied, batch-specific Janoshik report, listed on our lab-reports page at /coa.
Current listing: Current vial sizes, stock status and prices are shown on the product page.
EU shipping: Shipped from within the EU customs territory with tracked delivery; see the shipping page for current destination-specific estimates.

Frequently Asked Questions